924759-42-2

BT44 (5-25 mg/kg; s.c.; every second day for 10, 42 or 14 days) alleviates sensory signs in the SNL and STZ models of neuropathic^[1].
BT44 (12.5 or 25 mg/kg; s.c.; every second day for 10 days) protects IB4-positive neurons in DRGs of animals with experimental neuropathy^[1].
BT44 (0.1 and 0.3 μg/24 h; infuse into the right dorsal striatum for 14 days) reverses amphetamine-induced motor imbalance and seems to protect dopaminergic fibers in the striatum in 6-OHDA rat model of Parkinson’s disease^[2].
BT44 (10 mg/kg; i.v.) penetrates the blood-brain barrier and is rapidly eliminated from the circulation (half-life (t_1/2) = 0.72 h) and brain (t_1/2 = 0.47 h) in rats^[2].